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Circadian clocks coordinate mammalian behavior and physiology enabling organisms to
anticipate 24-hour cycles. Transcription-translation feedback loops are thought to drive these
clocks in most of mammalian cells. However, red blood cells (RBCs), which do not contain a
nucleus, and cannot perform transcription or translation, nonetheless exhibit circadian redox
rhythms. Here we show human RBCs display circadian regulation of glucose metabolism,
which is required to sustain daily redox oscillations. We found daily rhythms of metabolite
levels and flux through glycolysis and the pentose phosphate pathway (PPP). We show that
inhibition of critical enzymes in either pathway abolished 24-hour rhythms in metabolic flux
and redox oscillations, and determined that metabolic oscillations are necessary for redox
rhythmicity. Furthermore, metabolic flux rhythms also occur in nucleated cells, and persist
when the core transcriptional circadian clockwork is absent in Bmal1 knockouts. Thus, we
propose that rhythmic glucose metabolism is an integral process in circadian rhythms.
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C ircadian rhythms allow species to adapt their physiology todaily environmental variation tied to the Earth’s rotation1.They govern essential processes, including the regulation
of hormones, the sleep-wake cycle, cell division, and immunity2,3.
Disruption of circadian rhythms is associated with metabolic
syndrome, obesity, type 2 diabetes and various neurological dis-
orders4,5. Circadian rhythms are thought to be driven by
transcriptional-translational feedback loops (TTFLs), whereby
rhythmic expression of clock gene products regulate the expres-
sion of associated genes in an approximately 24-h cycle6. How-
ever, genetic studies of circadian clocks in various model
organisms (cyanobacteria, Drosophila, Arabidopsis, mice, and
humans) has shown that most clock genes are not evolutionarily
conserved across distinct phylogenetic kingdoms, and TTFL
components are not shared between organisms7. Several studies
implicate non-transcriptional components in circadian rhythmi-
city. These include post-translational circadian oscillation of
cyanobacterial KaiC phosphorylation and cytosolic mechanisms
such as Ca2+/cAMP8,9. However, there is limited homology of
these posttranslational clock components across various model
organisms10, and thus it has been challenging to study post-
translational aspects of circadian biology in nucleated mamma-
lian cells.
We previously found circadian rhythms in reduction-oxidation
(redox) cycles of peroxiredoxin proteins in mammalian red blood
cells (RBCs), which do not have nuclei and do not produce new
RNA or protein11. We also found similar posttranslational per-
oxiredoxin rhythms in various prokaryotes and eukaryotes
commonly used as circadian model systems10,12. This suggests
that redox processes are important in circadian rhythm genera-
tion across phylogenetic boundaries, and may have evolved ~2.5
billion years ago with specific mechanisms to counteract the
deleterious consequences of oxidative stress7,10. However, what
drives circadian timing of redox balance is unclear. Metabolism is
one such important player that may be a connecting node
between redox processes and the clockwork.
In this study, we sought to understand the metabolic basis of
peroxiredoxin oscillations in human red blood cells. To do this,
we characterized circadian regulation of metabolites in human
red blood cells using metabolomics and computed metabolic
fluxes. Importantly, we uncovered rhythmic oscillations in gly-
colysis and pentose phosphate pathway metabolites and meta-
bolic fluxes with distinct and opposite phases. Moreover, we find
that circadian regulation of metabolic switching in glycolysis and
pentose phosphate pathways is tightly coupled to redox oscilla-
tions. Perturbing key components of these metabolic pathways
results in loss of redox rhythms in human RBCs. We then
examined nucleated mammalian cells and found analogous
metabolic oscillations, with and without the core TTFL clock
feedback circuit. Thus, we find that circadian metabolic flux
rhythms persist regardless of whether the TTFL is present.
Results
Metabolomics reveals circadian regulation of metabolites in
human RBCs. Because human RBCs cannot perform transcrip-
tion and/or protein synthesis, they completely rely on metabolic
processes to combat reactive oxygen species (ROS), created by
auto-oxidation of hemoglobin, for survival11,13,14. As such, we
hypothesized that metabolism exhibits non-transcriptional oscil-
lations in RBCs. To determine whether metabolism exhibits a
daily rhythm, we first analyzed the RBC metabolome in samples
from human subjects. We collected fresh blood samples and
incubated purified RBCs in constant conditions (at 37 °C in
continuous darkness) ex vivo to exclude any temporal cues that
could drive oscillations (Fig. 1A)11,15–17. Thus, any measurements
made reflect self-sustained rhythms in the isolated cells. We
sampled cells every 3 h over two days and performed untargeted
metabolite profiling by gas chromatography (GC) and liquid
chromatography (LC) mass spectrometry (MS). We detected
1,698 features that had a coefficient of variation <30% in quality
control samples. This included 533 features from negative mode
LC-MS and 1074 from positive mode, with an additional 91 from
GC-MS (Supplementary Fig. 1). We identified 43 rhythmic
metabolites (padj < 0.05) using Rhythmicity Analysis Incorporat-
ing Nonparametric methods (RAIN)18 (Fig. 1B, and Supple-
mentary Table 1).
The majority of rhythmic metabolites included carbohydrates
and redox metabolites. Overall, 20% (43 of 213 known detected
metabolites) of the RBC metabolome displayed a 24-h cycle. This
is consistent with the circadian metabolome of human blood
plasma (∼15–22%)19,20. Since RBCs cannot perform fatty acid
synthesis, protein synthesis, the citric acid cycle, or nucleotide
synthesis, these aspects of metabolism are not under circadian
control. Principal Components Analysis (PCA) revealed that the
corresponding time points from the first and second days
grouped together, and that the major component separating the
cycling metabolome was time of the day (Fig. 1C). Pathway
enrichment analysis of rhythmic metabolites identified an
enrichment in glycolysis and PPP pathways (false discovery rate,
FDR < 0.01), but not others (Fig. 1D, E).
Glucose displayed a well-defined 24-h oscillation (P= 0.005 by
RAIN), with glucose-6-phosphate (G6P) showing a similar phase,
albeit with reduced rhythmicity (P= 0.0369 by RAIN) (Fig. 2A).
Importantly, ribose-5-phosphate (R5P), a principal metabolite in
the PPP, exhibited daily cycling in anti-phase to G6P (Fig. 2A, B).
In addition, many other metabolites in the glycolytic pathway
showed robust circadian cycles over at least two days (Fig. 2A,
Supplementary Table 1). Together, these data show that there is
circadian oscillation of specific glycolytic and PPP metabolites in
human RBCs.
Rhythmic glycolysis and PPP fluxes in human RBCs. Metabo-
lites levels are dependent on the input of fluxes through metabolic
pathways, and these metabolic pathway fluxes are considered a
crucial biological function, and are under strong evolutionary
selection procedure21,22. To determine how rhythmic abundance
of metabolites occurs, and the enrichment of metabolites in dif-
ferent circadian phases, we assessed the rate of flow through
glycolysis and PPP. We employed an established labeling model
to measure metabolic fluxes in human RBCs by nuclear magnetic
resonance spectroscopy (NMR)23. Under constant conditions, as
described above, we took samples at 4 h intervals over three days
to determine flux through glycolysis and PPP (Fig. 3A). We
collected samples at least 24-h after incubating cells in 11 mM
labeled glucose. When 2-13C1-glucose is metabolized by glyco-
lysis, it produces lactate labeled at position 2 (2-13C1-lactate; C2-
lactate). In contrast, 3-13C1-lactate (C3-lactate) is produced when
the labeled glucose passes through PPP (Fig. 3B). We quantified
these differentially labeled lactates at a chemical shift (δ) of 71.2
(C2-lactate) and 22.8 (C3-lactate) using NMR (Fig. 3B). We then
calculated fluxes through PPP and glycolysis. We found circadian
oscillation of glycolysis (P= 0.009 by RAIN), and PPP in anti-
phase, for three consecutive days (Fig. 3C).
Peroxiredoxin oxidation (PRDX-SO2/3) in RBCs from the same
samples demonstrated circadian rhythms (Fig. 3D, Supplemen-
tary Figs. 2 and 3). We validated circadian flux measurements by
performing an independent experiment with 11 mM 1,2-13C2-
Glucose, assayed by GC-MS (Fig. 3E–G). When 1,2-13C2-glucose
is administered to RBCs, glycolysis generates m+ 2 lactate, while
PPP generates m+ 1 lactate (Fig. 3E)24. GC-MS also
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demonstrated circadian fluxes through glycolysis and PPP (P=
0.042 by RAIN; Fig. 3F). Corresponding peroxiredoxin oxidation
(PRDX-SO2/3) immunoblots also revealed circadian rhythms
(Fig. 3G and Supplementary Figs. 4 and 5). Indeed, NMR and
GC-MS readouts are very similar when compared side-by-side
(Fig. 3H).
PPP flux peaked during the circadian day (phase ~11) whereas
glycolytic flux peaked at night (phase ~23). Peroxiredoxin
oxidation was highest during the day, aligned with the PPP flux
peak (phase ~13). We saw a progressive decrease in glucose in the
surrounding medium in our single pulse labeling experiments
(Supplementary Fig. 6). Because this could impact measurements
in flux models, we next performed a dynamic glucose pulse
experiment using two different tracers: 11 mM 1,2-13C2-glucose
or 1-13C1-glucose (Fig. 4A, B). In concordance with our results
using a single pulse of glucose at the beginning of the experiment,
we found circadian oscillations of glycolytic flux using the pulsed
glucose time courses (Fig. 4A, B).
Circadian rhythms in mouse RBCs have also been
reported16,17. To determine if metabolic flux varies over the day
in circulating RBCs in vivo, we took blood from mice at opposite
phases of the circadian cycle—in the middle of the subjective day
(CT06) or night (CT18)—and then labeled RBCs with glucose
and determined flux by GC-MS (Fig. 4D). As in our ex vivo
experiments, we found at least a 2-fold difference in flux in
labeled cells from opposite circadian phases (Fig. 4D). Collec-
tively, these results indicate that there is a circadian rhythm of
metabolic flux through glycolysis and PPP in red cells, both
Fig. 1 Redox and metabolic rhythms in human red blood cells (RBCs). A Experimental scheme for untargeted Human RBCs circadian sampling. RBCs from
n= 3–4 human subjects were incubated with 11 mM glucose and kept under constant conditions (37 °C in continuous darkness) and sampling was
performed every 3 h. Untargeted metabolite analysis was performed using GC-MS and LC-MS. B Heatmap of all cycling features ordered by the phase of
the oscillation. Features extracted from spectra using Progenesis QI (LC-MS) and MassHunter (GC-MS) were used for the rhythmicity analysis using RAIN
algorithm (*P < 0.05, FDR= 0.2). Data are Z-score normalized log10 intensities. C Principal components analysis (PCA) of the cycling metabolome. The
two major components separate the data into samples corresponding to the circadian day (left, orange) and night (right, green) time-points. D Pathway
analysis performed using Metabolite Set Enrichment Analysis (MSEA) using only identified 24-h rhythmic metabolites. The color bar represents the
significance level, as shown in the table. *FDR < 0.01. E Table representing the enriched metabolic pathways with the corresponding metabolite hits,
P values and FDR.
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in vivo and ex vivo, which may drive circadian metabolite profiles
that we uncovered in these pathways.
Redox couples cellular metabolism in human RBCs. Peroxir-
edoxins in red blood cells play a crucial role to maintain redox
balance by neutralizing H2O2 generated in part by auto-oxidation
of hemoglobin14. Peroxiredoxin oxidation exhibits circadian
rhythms, prompting the question of how coupling between
metabolic cycles and redox state is achieved. To understand this
link, we investigated the interrelationship between glucose-
metabolizing pathways in RBCs and peroxiredoxin redox state.
We first inhibited flux through glycolysis using heptelidic
(koningic) acid (HA), a potent inhibitor of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH)25,26 (Fig. 5A). Metabolic
inhibition experiments were performed on RBCs isolated from
fresh blood samples collected from human subjects and metabolic
inhibitors were added at the start of the experiment (Fig. 5B). We
found that fluxes through glycolysis and PPP became arrhythmic
(P= 0.865 by RAIN) after treatment with 1.9 µM HA (Fig. 5C;
only glycolytic flux shown for clarity).
We then inhibited flux through PPP using 10 mM 6-
aminonicotinamide (6AN), an inhibitor of the two NADPH-
producing enzymes in PPP (Fig. 5A)27,28. The amplitude of flux
oscillations was reduced and non-rhythmic (P= 0.127 by RAIN;
Fig. 5C). Peroxiredoxin oxidation in cells treated with these
inhibitors was also affected, abolishing 24-h patterning (Fig. 5D,
Supplementary Fig. 7). Interestingly, although HA treatment
caused arrhythmicity (P= 0.231 by RAIN), 6AN prolonged
period to 36 h (P < 0.001 by RAIN) compared to control cells
(Fig. 5D). Importantly, the inhibitors did not affect RBC viability
at the doses used (Supplementary Fig. 8), and they caused
differential changes in the RBC metabolome, demonstrating their
Fig. 2 Rhythmic accumulation of central carbon metabolites in human red blood cells (RBCs). A Selected significant rhythmic metabolites (*P < 0.05) in
human RBCs analyzed by an untargeted metabolomics approach using GC-MS and LC-MS platforms. Rhythmicity analysis was performed using RAIN
algorithm (*P < 0.05, FDR= 0.2). RBCs were synchronized for 24 h and then sampling was performed for every 3 h over a period of 48 h. Relative log10
normalized intensities for metabolites are presented. Glycolytic metabolites are represented in blue and PPP metabolites in red. List of identified rhythmic
metabolites presented in Supplementary Table 1. Glucose (n= 3 replicates), G6P= glucose-6-phosphate (n= 4 replicates), 2,3-DPG= 2,3-
diphosphoglycerate (n= 3 replicates), Ribu5P= ribulose-5-phosphate (n= 4 replicates), R5P= ribose-5-phosphate (n= 3 replicates), pyruvate (n= 3
replicates), lactate (n= 3 replicates). B Correlation plot comparing selected glycolytic and PPP metabolites. Data are mean ± s.e.m.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20479-4
4 NATURE COMMUNICATIONS |          (2021) 12:377 | https://doi.org/10.1038/s41467-020-20479-4 | www.nature.com/naturecommunications
specificity for glycolysis and PPP. Furthermore, treatment with
either pathway inhibitor abolished of time of day variation in
metabolites (Fig. 5E). Similarly, temporal variation of ATP (which
reflects glycolytic energy output) was abolished by HA, and
analogously 6AN had an identical effect on oxidized glutathione
(an output of the PPP) (Fig. 5F). Together, these results
demonstrate that there is tight coupling between core glucose
metabolism and peroxiredoxin oxidation rhythms in RBCs, and
that perturbing flux through glucose-metabolizing pathways has a
potent effect on redox rhythms.
In addition to PRDX oxidation rhythms in RBCs, we also
identified 24-h oscillations of the redox coenzymes NADH and
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NADPH previously11. Since RBCs do not possess organelles, such
as mitochondria, NADH and NADPH originate from glycolysis
and PPP29. The redox coenzymes NADH and NADPH produced
by glycolysis and PPP are likely links between glucose metabolism
and redox cycling of peroxiredoxins. However, their respective
role in the generation of circadian rhythmicity in RBCs remains
undefined.
We first measured NADH and NADPH in RBCs every 4 h over
a period of 24 h after treating cells with the glycolytic and PPP
inhibitors, HA and 6AN, respectively (Fig. 6A). We did not find
discernible 24-h rhythms in either NADH or NADPH when cells
were treated with the inhibitors (Fig. 6B, C), although a residual
non-circadian (12-h) NADH rhythm appeared to persist in cells
treated with HA (Fig. 6B). This suggests coupling between cellular
metabolism and redox factors NAHD and NADPH. Thus,
rhythmic glucose flux is necessary for robust redox oscillations
(PRDX-SO2/3, NADH, and NADPH). To test whether the
converse is true, that redox oscillations are needed for flux
rhythms, we treated RBCs with a compound that inhibits PRDX
oxidation (conoidin A)30–33 and one that abolishes PRDX
oxidation rhythms (MG-132)17 in RBCs (Fig. 6D). Treatment
with either inhibitor resulted in non-rhythmic flux (Fig. 6E).
These data indicate that rhythmic glucose metabolism is a crucial
determinant of circadian redox rhythms, and reciprocally, redox
rhythms are required for flux rhythms in RBCs.
Metabolic flux rhythms in nucleated mammalian cells. We next
tested whether metabolic flux oscillations also occur in nucleated
cells. Human U2OS cells have been extensively used to investigate
molecular clock mechanisms, including small molecule screen-
ing28,34,35. Unlike RBCs, U2OS cells exhibit autonomous circa-
dian rhythms in gene transcription and translation. U2OS cells
also exhibit circadian PRDX oxidation rhythms28 and these redox
rhythms are intrinsically coupled to clock components through
reversible redox modifications36. As well as being essential redox
factors in RBCs, NADH and NADPH influence the activity of
transcription factors in nucleated cells by modulating the binding
of circadian components such as CLOCK and BMAL1 to the
genome37,38.
We therefore determined glycolytic and PPP fluxes in U2OS
cells. Cells were grown to confluence (i.e., non-dividing to exclude
contributions from the cell cycle), cultured for three days in
standard glucose (25 mM) medium, and then synchronized with a
15 min 100 nM dexamethasone pulse28. Then, we replaced
medium with that containing 25 mM 1,2-13C2-glucose. Beginning
24 h after synchronization, we took samples for 48 h and
measured metabolic flux (Fig. 7A). GC-MS analysis of cellular
extracts showed that glycolytic and PPP flux exhibit circadian
oscillations, as in RBCs (P < 0.001 by RAIN; Fig. 7B; only
glycolytic flux shown for clarity).
Glycolytic and PPP fluxes are independent of BMAL1 in
nucleated cells. Metabolic regulation is closely associated with the
circadian clock machinery, and REV-ERB proteins play critical
roles in feedback regulation of the core TTFL oscillator because
they are direct targets of BMAL1 and CLOCK transcription
factors39. Accordingly, recently developed REV-ERB agonists,
such as SR9011, alter circadian behavior and metabolism in mice
by affecting core clock genes40. We treated U2OS cells with
50 µM SR9011, which resulted in severe blunting of circadian
oscillations of the reporter Bmal1:luciferase (Bmal1:luc). The
effect was reversible on washing out the compound (Fig. 7C,
Supplementary Fig. 9). Of note, although higher concentrations of
SR9011 (e.g., 100 µM) completely abolished rhythms, recovery of
rhythms was not apparent on wash out because of cell death at
higher concentrations (Supplementary Fig. 9). Despite compro-
mised transcriptional rhythms in SR9011-treated cells, we found
persistent circadian rhythms of glycolytic and PPP fluxes
(Fig. 7D; only glycolytic flux shown for clarity).
To validate these results in a different model, we performed time
courses on skin fibroblasts from adult Bmal1−/− and Bmal1+/+
mice. BMAL1 (MOP3) is considered to be an essential component
of the circadian transcriptional clockwork, and is necessary for
behavioral rhythms41. Bmal1+/+ and Bmal1−/− fibroblasts were
grown to confluence, cultured for three days in standard glucose
(25mM) medium, and then synchronized for 15min with a
100 nM dexamethasone pulse28,42. We then replaced medium with
that containing 25mM 1,2-13C2-glucose (Fig. 7E). Twenty-four
hours after synchronization, we took samples every three hours for
48 h and measured metabolic flux (Fig. 7E). We found robust
rhythms in relative glucose flux in both Bmal1+/+ and Bmal1−/−
cells (Fig. 7F). These findings are consistent with data suggesting
residual, but non-circadian, oscillations of glycolytic metabolites
(biphosphoglycerate, ATP, ADP, and lactate) in U2OS cells when
Bmal1 was knocked down by RNA interference (RNAi)35. More-
over, non-canonical circadian mRNA, protein and post-
translational rhythms (including PRDX-SO2/3) were also reported
in Bmal1−/− cells and tissue42, showing that metabolic flux
oscillations are an additional type of BMAL1-independent circadian
rhythm.
Fig. 3 Circadian regulation of glycolysis and pentose phosphate pathways (PPP) fluxes in human red blood cells (RBCs). A Schematic showing
experimental protocol used to collect samples. RBCs from n= 3 human subjects were incubated with either 11 mM 2-13C1-glucose or 1,2-13C2-glucose
and kept under constant conditions (37 °C in continuous darkness) and sampling was performed every 4 h over 3 days period. B Schematic showing fate of
2-13C1-Glucose metabolized through glycolysis and the pentose phosphate pathway (PPP). Metabolic fluxes for glycolysis and PPP were quantified
by 13C-NMR (nuclear magnetic resonance) spectroscopy. When 2-13C1-glucose is used as a tracer, it is metabolized via glycolysis and produces singly
labeled 13C1-2-lactate with chemical shift, δ= 71.2. The same 2-13C1-glucose metabolized through the PPP produces singly labeled 13C1-3-lactate with
chemical shift δ= 22.8. C Rhythmic glycolytic and PPP fluxes (P= 0.009) in RBCs measured by NMR. P-values were obtained from rhythmicity analysis
using RAIN algorithm. Graph bars present mean ± s.e.m (n= 3 biological replicates). D Rhythmic PRDX oxidation used as a control for circadian rhythmicity
in RBCs for measuring metabolic fluxes by NMR experiment. P-values were obtained from rhythmicity analysis using RAIN algorithm. Data are presented
mean ± s.e.m (n= 3 biological replicates). E Schematic showing fate of 1,2-13C2-Glucose metabolized by glycolysis and the pentose phosphate pathway
(PPP). Metabolic fluxes were measured with GC-MS. When 1,2-13C2-glucose is used as a tracer, it is metabolized via glycolysis and produces doubly
labeled 2,3-13C2-lactate. The same 1,2-13C2-glucose metabolized through the PPP produces singly labeled 13C1-lactate. The glycolytic m+ 2 isotopomer of
13C2-lactate and the pentose phosphate pathway m+ 1 isotopomer of 13C1-lactate were thus used for flux measurements (see Methods). f Rhythmic
regulation of glycolysis and PPP fluxes in RBCs measured by GC-MS. P-values were obtained from rhythmicity analysis using RAIN algorithm. Data are
presented mean ± s.e.m (n= 3 biological replicates). G Rhythmic PRDX oxidation used as a control for circadian rhythmicity in RBCs for measuring
metabolic fluxes by GC-MS experiment. P-values were obtained from rhythmicity analysis using RAIN algorithm. Data are presented mean ± s.e.m (n= 3
biological replicates). H Comparison of glycolytic flux measurements in RBCs measured by NMR and GC-MS methods. This correlation figure is obtained
from Fig. 3C, F. Data are presented mean ± s.e.m (n= 3 biological replicates).
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Discussion
Although gene expression cycles are essential for the temporal
coordination of physiology, we and others have previously shown
that rhythms in redox balance is a cell-intrinsic phenomenon that
persists without any gene expression cycles in non-nucleated
mammalian red blood cells11,17. This circadian rhythm in redox
balance is seen across the domains of life, and cells have evolved a
number of defense mechanisms to counteract the deleterious
consequences of oxidative stress, including the use of peroxir-
edoxin proteins10,43,44. Among these processes, metabolism is a
key player, and is also evolutionarily conserved to maintain cel-
lular energy and survival45. However, how cytosolic rhythmic
redox balance interacts with metabolism has not been elucidated.
At different levels of biological organization, from the whole body
to single cells, a significant portion of metabolism is under cir-
cadian control, leading to the prevailing view that biological
cycles drive metabolic rhythms46,47. Indeed, recent reports sug-
gest rhythmic metabolites from lipid metabolism, and NAD+
biosynthesis from mitochondrial metabolism, are controlled by
the clock48.
However, such circadian control of metabolism cannot happen
in human red blood cells, where there are no gene expression
cycles and/or organelles such as mitochondria. We uncovered a
circadian metabolome in human RBCs and also showed circadian
rhythms of glycolysis and PPP metabolites, indicating that cel-
lular metabolism may be an integral part of non-transcriptional
circadian clocks. RBCs depend on glycolysis for ATP, and on the
PPP to maintain the redox balance through NADPH29. Because
metabolites are functionally dependent on input of metabolic
fluxes through a number of enzyme pathways, the contribution of
fluxes in generating cycling metabolites is important. Our labeling
experiments with human RBCs revealed rhythmic regulation of
Fig. 4 Rhythmic metabolic fluxes in human RBCs subjected to dynamic glucose labeling. A Schematic showing the sampling protocol for dynamic
glucose pulse labeling and below calculated fluxes from these labeling experiments. Oscillations of glycolytic fluxes using either 1,2-13C2-glucose labeling
are shown below the schematic. Data for 1,2-13C2-glucose flux are mean ± s.e.m (n= 3 biological replicates). Samples were entrained with 12-h: 12-h 37 °C:
32 °C and maintained at constant conditions. B Independent validation of metabolic flux with isotope 1-13C1-Glucose. Schematic of 1-13C1-Glucose labeling
and calculation of PEP isotopomer ratio to calculate glycolytic flux ratio. G6P=Glucose-6-phosphate, G3P=Glyceraldehyde 3-phosphate, F6P= Fructose-
6-phosphate, DHAP=Dihydroxyacetone phosphate, PEP= Phosphoenolpyruvate, R5P= Ribose-5-phosphate, 6PG= 6-Phosphogluconate. Glycolytic
(fgly) flux ratio for 1-13C1-glucose experiments was determined using the mass isotopomer distribution of Phosphoenolpyruvate (PEP). Data for 1-13C1-
glucose flux ratio are mean ± s.e.m (n= 4 biological replicates). P-values report significance by ANOVA (effect of time). C Schematic showing the sampling
protocol for calculated fluxes from 1,2-13C2-glucose labeling experiments. Oscillations of glycolytic fluxes are shown below the schematic. Data for 1,2-13C2-
glucose flux are mean ± s.e.m (n= 3 biological replicates). P-values were obtained from rhythmicity analysis using RAIN algorithm Note these data are
replotted from Fig. 3F to compare phase of glycolytic flux to Fig. 4A. D Measurement of RBC flux in circulating mouse RBCs at opposite circadian phases.
Mouse RBCs (n= 3 biological replicates) were harvested at opposite phases of the circadian cycle (see schematic): CT06 and CT18 (CT, circadian time:
subjective day CT00-CT12; subjective night CT12-24). P-values report significance by one way ANOVA.
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glycolytic and PPP flux. These fluxes have opposite phases, with
the PPP reaching its peak during the day, aligned with peroxir-
edoxin peak oxidation, while glycolysis is active during the night
(Supplementary Fig. 10).
It is likely that RBC redox rhythms are synchronized to human
physiology through blood oxygen levels. Indeed, the latter exhibit
a 24-h pattern, and oxygen levels reach their maximum in the day
(during biophysical peak activity), and decrease to their lowest
levels during at night49. This leads to greater oxygenation of
hemoglobin in RBCs, and the generated ROS are likely to entrain
cellular redox state and oxidation of peroxiredoxin to synchronize
the RBC 24-h oscillations in oxidative stress to body physiol-
ogy11,17. To counteract cellular oxidative damage, rhythmic
NADPH production by the PPP may thus be required to prevent
cellular damage caused by the daily auto-oxidation of hemoglo-
bin50–52.
Our results show that during the circadian night, when oxygen
is lowest, glycolysis reaches its peak. Active dynamic re-routing of
carbohydrate flux is key to counteracting oxidative stress, and our
results indicate that switching metabolic flux through PPP and
Fig. 5 Metabolic inhibition abolishes circadian metabolic flux and PRDX oxidation rhythms in human red blood cells (RBCs). A Schematic showing key
steps and metabolites in glycolysis and the pentose phosphate pathway (PPP) and the points at which the glycolytic inhibitor, heptelidic acid (HA) and the
PPP inhibitor, 6-aminonicotinamide (6AN), act in the pathways. G6P=Glucose-6-phosphate, F6P= Fructose-6-phosphate, FBP= Fructose-1,6-
biphosphate, DHAP=Dihydroxyacetone phosphate, 6PGL= 6-Phosphogluconolactone, 6PG= 6-Phosphogluconate, GAP=Glyceraldehyde-3-phosphate,
GAPDH=Glyceraldehyde 3-phosphate dehydrogenase, G6PD=Glucose-6-phosphate dehydrogenase, TK= Transketolase, TA= Transaldolase.
B Schematic for sample collection. Freshly prepared human RBCs treated with metabolic inhibitors 1.9 µMHA, 10mM 6AN, or vehicle control (DMSO) and
then kept under constant conditions (37 °C, continuous darkness) and sampling was performed every 4 h. C Effect of inhibitors on metabolic fluxes through
glycolysis measured by GC-MS. P-values were obtained from rhythmicity analysis using RAIN algorithm. Graph bars present mean ± s.e.m (n= 4 biological
replicates). D The effect of metabolic inhibitors on peroxiredoxin (PRDX) oxidation in RBCs was measured by immunoblotting for PRDX-SO2/3 dimer. Blots
are shown with their respective loading controls (Coomassie blue gel images). Graph bars present mean ± s.e.m (n= 3 biological replicates). Full blots from
all subjects are shown in Supplementary Fig. 7. P-values were obtained from rhythmicity analysis using RAIN algorithm. E Effect of HA and 6AN on the RBC
metabolome. Principal Components Analysis (PCA) plot showing components 1 and 2 for all metabolomic samples showing good separation between
control, HA and 6AN treated samples. Circadian time dependent changes were observed in control along PC1 (CT 24 vs. CT 36), while circadian time
dependent changes are abolished in samples treated with metabolic inhibitors. Ellipses indicate the 95% confidence intervals of each grouping of samples
on the plot. F Time-dependent changes in ATP and oxidized glutathione at CT24 and CT36. Controls show significant (P < 0.01) temporal variation of
abundance of ATP and oxidized glutathione, while samples treated with metabolic inhibitors had no time-dependence (not significant, n.s). P-values report
significance by one way ANOVA. Graph bars present mean ± s.e.m (n= 4 biological replicates).
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glycolysis over the circadian cycle could fulfill this goal (Supple-
mentary Fig. 10). GAPDH functions as a metabolic switch for re-
routing carbohydrate52. We have shown that inhibiting GAPDH
results in arrhythmic metabolic fluxes, which leads to arrhythmic
redox balance as shown by flat NADPH, NADH, and peroxir-
edoxin oxidation profiles. Thus, our data suggest daily cross-talk
of glucose metabolism and redox factors is required to maintain
circadian oscillations in human RBCs.
In eukaryotes, prevailing clock models revolve around
transcription-translation feedback loops (TTFLs)6. How cell
metabolism couples to rhythmic peroxiredoxin state and whether
these metabolic rhythms are independent of TTFL was unclear.
Our experiments with U2OS cells reveal rhythmic regulation of
glycolysis and PPP fluxes in nucleated human cells. Furthermore,
experiments using Bmal1 knockout mouse cells show that circa-
dian flux rhythms persist in the absence of a functional TTFL
network. Indeed, glycolysis and PPP fluxes have higher ampli-
tudes in comparison to control (Bmal1+/+) cells. We recently
reported circadian oscillations of the transcriptome, proteome
and phosphoproteome of Bmal1 knockout mouse cells and tis-
sue42. The flux data in Bmal1 knockout cells presented in this
study thus strongly support the notion of TTFL-independent
circadian timekeeping mechanisms. Given that metabolic oscil-
lations are present in both nucleated cells genetically lacking a
functional TTFL53, and in the complete absence of transcription
or translation (as shown here), the most parsimonious explana-
tion is that rhythmic metabolism is at the core of circadian
timekeeping. Thus, our work paves the way to explore the role of




Contact and materials availability. Further information and requests for resources
and reagents should be directed and will be fulfilled by the senior author, Akhilesh
B Reddy (areddy@cantab.net). This study did not generate new unique reagents.
Experimental model and subject details
Human participants and ethics statement. Studies were conducted in accordance
with the principles of the Declaration of Helsinki, with approval from the Health
Research Authority’s (UK) Research Ethics Committee (Reference number 12/EE/
0370) and local ethical approval by The Francis Crick Institute’s Ethics Review
Board. The Francis Crick Institute is licensed by the Human Tissue Authority
(HTA) to store human samples for the purposes of research (License number
12650). The research complies with all requirements of the relevant HTA Code of
Practice. All volunteers provided written informed consent after receiving a par-
ticipation information sheet containing detailed information of the study proce-
dures. Participants were screened for self-reported health issues including sleep
disorders, night shift work, and regular high alcohol consumption, and excluded if
they met any of these criteria. Sample size for all experiments mentioned at cor-
responding experimental figure legends.
Human red blood cells (RBC) culture. Fresh blood samples (9–10 ml) were collected
from each healthy volunteer in 10 ml tubes containing trisodium citrate (Sarstedt,
S-Monovette 02.1067.001). RBCs from each donor were separately isolated using 5
ml of Histopaque (Histopaque-1007, density 1.077 g/ml, sigma) by density gradient
centrifugation for 15 min at 700 × g. The obtained RBC pellet was washed three
times using 10 ml sterile PBS (Sigma-Aldrich). The washed pellet was diluted to
9 ml with Krebs–Henseleit Buffer (290 mOsm, pH 7.40) supplemented with
100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich) and 0.1% BSA
(Sigma-Aldrich). 500 μl of anti-CD15 Dynabeads (Life Technologies 11137D) were
added to each tube to remove any remaining nucleated cells, which were extracted
Fig. 6 Metabolic inhibition abolishes rhythmic redox cofactor
accumulation in human red blood cells (RBCs). A Schematic showing
experimental protocol used to collect samples. RBCs from n= 3–4 human
subjects were incubated with 11 mM 1, 2-13C2-glucose and kept under
constant conditions (37 °C in continuous darkness) and sampling was
performed every 4 h. Cells were treated with metabolic inhibitors, HA and
6AN at the starting of the experiment. B Effect of metabolic inhibitors HA
and 6AN on the rhythmicity of the redox coenzyme, NADH. Graph bars
present mean ± s.e.m (n= 6 biological replicates) C Effect of metabolic
inhibitors HA and 6AN on the rhythmicity of the redox coenzyme, NADPH.
Graph bars present mean ± s.e.m (n= 6 biological replicates). D Schematic
showing experimental protocol used to collect samples after treating with
inhibitors Conoidin A and MG-132. E RBCs were treated with inhibitors of
PRDX oxidation (Conoidin A) or PRDX oxidation rhythms (MG-132) and
their effect on glucose flux was assessed. All data are mean ± s.e.m. (n= 4
biological replicates). The 24-h rhythmicity P-value (determined by RAIN)
for each profile is shown with each plot, in addition to the best fit period of
the rhythm if this was not 24 h. ns, not significant (P > 0.05).
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after 15 min incubation with the aid of a magnet (Life Technologies). Krebs-
Henseleit Buffer containing 11 mM D-Glucose (Sigma-Aldrich K3753) was used
for culturing RBC and un-targeted metabolite profiling experiments. For metabolic
labeling experiments, unlabeled D-glucose was replaced with either 11 mM U-13C6-
D-glucose (99%, CLM-1396, CK Isotopes Ltd) or 2-13C1-D-glucose (99%, CLM-
504, CK Isotopes Ltd). Different volumes of purified RBCs were used for untar-
geted metabolite analysis (1 ml of RBC per sample), metabolic flux assay experi-
ments with NMR (1 ml of RBC per sample) and GC-MS (200 μl of RBC per
sample). RBC samples were maintained at 37 °C in a microprocessor-controlled
incubator (Eppendorf Galaxy 170 R) in complete darkness, in sealed tubes, for
sampling. For metabolic inhibition experiments, heptelidic acid was dissolved in
DMSO to make a stock solution. Compounds were diluted in Krebs-Henseleit
Buffer to their final concentration. Drugs were added to RBCs to reach a final
concentration of 10 mM 6-Aminonicotinamide (CAS 329-89-5, Sigma A68203), or
1.9 µM heptelidic acid (CAS 74310-84-2, Biovision 2215–1000), or 3 µM MG-132,
or 5 µM conoidin A. Control samples were treated with 0.5% DMSO.
Experiments with U2OS cells. Stably-transfected Bmal1:luc U2OS cells were a kind
gift of Dr Andrew Liu (University of Memphis). Cells were cultured in a humidified
5% CO2 incubator in Dulbecco’s Modified Eagle’s medium (DMEM) (Sigma
D6546) containing 4.5 g/l glucose, 1× Glutamax (Life Technologies 35050-038, 10%
Newborn Calf Serum (Sigma 12023 C), 100 U/ml penicillin and 100 μg/ml strep-
tomycin (Sigma P0781), 1× MycoZap Plus-PR (Lonza) and blasticidin 2 μg/ml. For
metabolic flux experiments, unlabeled glucose was replaced with 25 mM 1,2-13C2-
D-glucose (99%, CLM-504, CK Isotopes Ltd). For bioluminescence recordings,
U2OS cells were grown to confluence in 96-well plates in the above medium and
synchronized by changing the medium to Air Medium28,54: DMEM (Sigma D5030)
supplemented with 4.5 g/L glucose (Sigma G8644), 1× Glutamax (Life Technologies
35050-038), 10% Newborn Calf Serum (Sigma 12023 C), 100 U penicillin/ml and
100 μg/ml streptomycin, 0.5× B-27® Supplement (Life Technologies 17504-044),
20 mM HEPES (Sigma H0887), 1 mM Luciferin (Biosynth L8220), 1× Non-
Essential Amino acids (Sigma M7145), 0.035% NaHCO3 (Sigma S8761), 1×
MycoZap Plus-PR (Lonza) and blasticidin 2 μg/ml. For experiments using the
REV-ERB agonist SR9011 (Caymen Chemical 11930; CAS 1379686-29-9), the
compound was solubilized in DMSO and diluted in Air Medium to a final con-
centration of 50 or 100 μM. Control cells were treated with a matched con-
centration of DMSO. Bioluminescence assays were conducted in custom-made
light-tight Alligator bioluminescence recording systems (Carin Research Ltd,
Faversham, UK) composed of a CCD camera (Andor iKon-M 934) placed on the
top of Galaxy 170 R incubator (Eppendorf). All bioluminescence experiments were
performed at 37 °C in darkness. Plate luminescence images were captured every 30
min over seven days.
Experiments with mice. Animal studies were carried out in concordance with an
approved protocol from Institutional Animal Care and Use Committee (IACUC) at
Perelman School of Medicine at the University of Pennsylvania, or under license by
the United Kingdom Home Office under the Animals (Scientific Procedures) Act
1986, with Local Ethical Review by the Francis Crick Institute Animal Welfare &
Ethical Review Body Standing Committee (AWERB). Male C57BL/6J mice,
8–10 weeks old, were purchased from Charles River and allowed to acclimatize and
Fig. 7 Circadian regulation of metabolic flux in nucleated cells. A Human U2OS cells were synchronized with a 15 min dexamethasone pulse treatment
and their medium replaced with DMEM medium containing 25mM 1,2-13C2-glucose. They were then kept under constant conditions (37 °C, continuous
darkness) and sampled every 3 h, starting 24 h after the dexamethasone pulse (and glucose labeling). B Glycolytic and pentose phosphate pathway (PPP)
flux in U2OS cells was measured by GC-MS using the glycolytic m+ 2 isotopomer of 13C2-lactate and the pentose phosphate pathway m+ 1 isotopomer of
13C1-lactate (see “Methods” section). Data are mean ± s.e.m. (n= 3 biological replicates). The 24-h rhythmicity P-value (determined by RAIN) is shown
with the plot. C Treatment of U2OS cells with 50 µM of SR9011 resulted in severe damping of bioluminescence rhythms that was reversible on drug wash
out (indicated by arrow). Traces for cells treated with vehicle control (DMSO), and untreated cells, are also shown. Data are mean of n= 4 biological
replicates (see Supplementary Fig. 9 for traces with error boundaries). D Metabolic flux in cells treated with SR9011 (or vehicle control). P-values were
obtained from rhythmicity analysis using RAIN algorithm. E Adult skin fibroblasts from Bmal1+/+ and Bmal1−/− mice were synchronized for a 15 min
with dexamethasone and their medium replaced with DMEM medium containing 25mM 1,2-13C2-glucose. Cells were then kept under constant conditions
(37 °C, continuous darkness) and sampled every 3 h, starting 24 h after the dexamethasone pulse (and glucose labeling. F Glycolytic flux in adult skin
fibroblasts from Bmal1+/+ and Bmal1−/− mice. Metabolic flux measured by GC-MS. Flux data are mean ± s.e.m. (n= 3 biological replicates).
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entrain in a 12-h light-dark cycle (LD). Light intensity during light and dark
periods was 200 and <3 lux, respectively. Humidity and temperature (21 ± 1 °C)
were kept within standard ranges. After 3 weeks, mice were transferred to constant
darkness (DD; dim red light, <3 lux) and on the second day of DD blood was
collected by cardiac puncture under terminal anesthesia (sodium pentobarbital,
170 mg/kg, intraperitoneal) at CT24 and CT36.
Experiments with Bmal1−/− mouse skin fibroblasts. Bmal1+/+ and Bmal1−/− adult
mouse skin fibroblasts (MSF) cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM) containing 10% (v/v) HyClone III Serum (Analab; Cat #
SH30109.03), 1/100 Glutamax-I (Invitrogen; Cat # 35050-038), 1/100 Penicillin-
Streptomycin (SIGMA; Cat # P4333) and 1/500 MycoZap™ (Lonza; Cat # VZA-
2022) in multiple six-well plates until fully confluent (n= 3, per time-point, per
genotype). Confluent MSF cells were treated with 100 nM (final concentration) of
dexamethasone (DEX) for 15 min to synchronize the cells. MSF cells were then
washed three times with PBS (37 °C) and were incubated in HEPES-buffered
Medium; 1× DMEM powder (SIGMA; Cat # D5030), 5 mg/ml 1, 2-13C2 (99%)
D-glucose (Cambridge Isotope Laboratories, Cat # CLM-504-1), 0.35 mg/mL
sodium bicarbonate, 0.01M HEPES, 5% (v/v) HyClone III Serum, 1/100 Glutamax-
I, 1× B-27 supplement (LifeTech Cat # 17504-044), 1× Non-Essential Amino acids,
and 1/500 MycoZap™, pH 7.4 (adjusted with HCl) and osmolality 350 mOsm
(adjusted with NaCl) at 37 °C under DD cycle. Twenty-four hours after the DEX
treatment, MSF cells were harvested at every three-hour interval for two days for
subsequent metabolic flux analysis.
Metabolite extraction for untargeted metabolite profiling. At each time point,
1.5 ml Eppendorf tubes containing 1 ml of purified RBCs in Krebs-Henseleit Buffer
were collected from the incubator and samples were immediately centrifuged for 2
min at 375 × g at 4 °C. The supernatant was removed and the RBC pellet washed
twice with ice-cold PBS. RBC metabolite extractions were performed using a
reported protocol55 with slight modifications. Briefly, metabolites were extracted
from RBCs by adding 450 μl of methanol. Vortex mixed for 10 s to lyse the cells in
methanol. Immediately, 200 μl of chloroform and 200 μl of water was added to the
pellet at 4 °C, followed by sonication for 10 min and then vortexing for 20 min.
Samples were then centrifuged at 18,400×g for 20 min at 4 °C. The upper aqueous
layer was collected and lower chloroform layer (containing non-polar metabolites)
was discarded. Two more extractions were performed on the same RBC pellet with
50% methanol:water with vortexing for 20 min, and centrifugation at 18,400×g for
20 min at 4 °C. 13C5-15N-Valine was used as an internal standard during all
extractions. The three extracts were combined and dried with a vacuum con-
centrator (Concentrator plus, Eppendorf). The dried extracts were subsequently
used for GC-MS and LC-MS analysis for metabolite profiling.
UPLC-MS based data acquisition for untargeted metabolite profiling. Dried
samples were reconstituted in 500 μl methanol:water (1:1, v/v). LC-MS analysis was
conducted using a Dionex UltiMate Liquid Chromatography (LC) system coupled
to a Q-Exactive Orbitrap mass spectrometer (both Thermo Scientific), adapted
from a reported method56. LC separation was performed using hydrophilic
interaction chromatography (HILIC) on a ZIC-pHILIC column (150 mm×4.6 mm,
5 μm particle size; Merck Sequant) with a gradient solvent A (20 mM ammonium
carbonate in water; Optima HPLC grade, Sigma Aldrich) and solvent B (acetoni-
trile; Optima HPLC grade, Sigma Aldrich). A 15 min elution gradient of 80 to 20%
Solvent B was used, followed by a 5 min wash of 5% Solvent B and 5 min re-
equilibration. Other LC parameters were: flow rate 300 μl/min; column tempera-
ture 25 °C; injection volume 10 μl; auto sampler temperature 4 °C. MS was per-
formed with positive/negative polarity switching using a HESI II probe. MS
parameters were: spray voltage 3.5 kV and 3.2 kV for positive and negative modes,
respectively; probe temperature 320 °C; sheath and auxiliary gases were 30 and 5
arbitrary units, respectively; full scan range: 70 to 1050 m/z with settings of AGC
target and resolution as Balanced and High (3 × 106 and 70,000) respectively. Data
was recorded using Xcalibur 3.0.63 software (Thermo Scientific). To enhance
calibration stability, lock-mass correction was also applied to each analytical run
using ubiquitous low-mass contaminants. Parallel reaction monitoring (PRM)
parameters: resolution 17,500; collision energies were set individually in high-
energy collisional dissociation (HCD) mode.
GC-MS based data acquisition for untargeted metabolite profiling. Dried
sample extracts were used for GC-MS analysis. Untargeted metabolite profiling was
performed by GC-MS using an Agilent 7890A-5975C GC-MSD after derivatization
of metabolites with methoxyamine hydrochloride (20 mg/ml in pyridine, both
Sigma) and N,O-bis-(trimethylsilyl)trifluoroacetamide (containing 1% trimethyl-
chlorosilane)57. GC separation was achieved using an Agilent DB-5 MS column
(30 m × 0.25 mm × 0.5 μm). The GC oven temperature program was: 70 °C, 2 min
hold; ramp 12.5 °C/min to 295 °C, 0 min hold; ramp 25 °C/min to 320 °C, 3 min
hold. Other GC parameters were: injection volume 1 μl; inlet temperature 270 °C;
Helium was used as a carrier gas at a flow rate of 0.9 ml/min; transfer line tem-
perature 280 °C. Electron impact ionization was used for mass spectrometry
detection with scan range m/z 50–565.
Metabolic flux measurements with NMR. For RBC metabolic flux experiments,
cultures were incubated with Krebs-Henseleit Buffer containing 11 mM 2-13C1-D-
glucose and at each time point a 1.5 ml Eppendorf tube containing 1 ml RBCs was
collected from the incubator, and immediately centrifuged for 2 min at 4 °C at
375 × g. The supernatant was collected and the pellet washed with ice-cold PBS two
times and centrifuged again for 2 min at 4 °C and at 375 × g. The RBC pellet and
was then immediately flash frozen in liquid nitrogen. Frozen samples stored at
−80 °C till the analysis. Frozen samples were thawed at 4 °C, and then placed in a
boiling water bath for 9 min to lyse cells and halt enzymatic activity23,58. Boiled
lysates were sonicated for 10 min at 4 °C on ice, followed by vortex mixed for
10 min. Samples were then centrifuged for 20 min at 18,400 × g at 4 °C. Nine-
hundred microliter of each supernatant was dried in a vacuum concentrator
(Concentrator plus, Eppendorf). Dried sample extracts were suspended in 750 μl
D2O (Sigma 151882) containing 0.05% of 3-(trimethlysilyl)-1-propanesulfonicacid-
d6 sodium salt (Sigma 613150). 13C-NMR spectroscopy was performed on a Bruker
AM-500 MHz spectrometer (Chemistry Department, University of Cambridge) or
a Bruker Avance III 600MHz spectrometer equipped with a 5 mm TCI Cryoprobe
(MRC Biomedical NMR Centre, Francis Crick Institute). Spectra were recorded
using a 30° 13C excitation pulse, 1 s acquisition time, and 3 s relaxation delay. The
spectra were 1H-broadband de-coupled using WALTZ16, which was also employed
during the relaxation delay to exploit the {1H}13C heteronuclear Overhauser
enhancement. Labeled C2-lactate, C3-lactate and alpha-anomers, beta-anomers of
glucose were identified and peak integrals were evaluated using the Bruker NMR
software package TopSpin 3.5.
Metabolic flux measurements with GC-MS. For RBC metabolic flux experi-
ments, cultures were incubated with Krebs–Henseleit Buffer containing 11 mM 1,2-
13C2-D-glucose and at each time point a 1.5 ml Eppendorf tube containing 200 µl
RBCs was collected from the incubator, and immediately centrifuged for 2 min at
4 °C at 375 × g. The supernatant was collected and the pellet washed with ice-cold
PBS two times and centrifuged again for 2 min at 4 °C and at 375 × g. The RBC
pellet and was then immediately flash frozen in liquid nitrogen and metabolites
extracted with 80% methanol:water followed by vortexing for 10 min, and then
centrifugation at 18,400 × g for 15 min at 4 °C. The aqueous layer was collected and
dried using a vacuum concentrator (Concentrator plus, Eppendorf).
For U2OS cell experiments, cultures were incubated with medium containing
25 mM 1,2-13C2-D-glucose and at each time point, culture supernatant was
removed and cells washed with ice-cold PBS three times. Immediately, 1 ml of ice-
cold 80% methanol:water (pre-cooled to −80 °C) was added and cells collected by
scraping into 1.5 ml Eppendorf tubes. Cells were flash frozen in liquid nitrogen and
stored at −80 °C.
For lactate isotopomer analysis, samples were derivatized as above and analyzed
on an Agilent GC-MSD. Parameters were as for untargeted GC-MS analyses above,
but with the following GC temperature gradient: 120 °C, 2 min hold; ramp 8 °C/
min to 180 °C; ramp 20 °C/min to 290 °C, 3 min hold. Selective ion monitoring
(SIM) for lactate isotopomers m+ 0 (unlabeled 12C-lactate), m+ 1 (13C1-lactate),
m+ 2 (13C2-lactate), m+ 3 (13C3-lactate).
Extracellular glucose from the media obtained from incubating RBCs with
U-13C-Glucose over a period of 72 h were analyzed after drying of 1 μl of medium.
Derivatization and GC-MS conditions were the same as mentioned above.
Pulse labeling experiments. Pulsed isotopic labeling was performed by feeding
RBCs with either 1,2-13C2-glucose or 1-13C-glucose. To minimize potential clock
resetting and perturbation of cells due to replacement of normal glucose medium
with labeled medium, we used conditioned medium, which was obtained by
incubating RBCs for 1 h in labeled medium and storing immediately at 4 °C.
Metabolic measurements for 1,2-13C2-glucose experiments were performed as
follows. Briefly, 800 μl of the upper fraction was dried in a speed-vacuum for 4.5 h.
The resulting dried sample was reconstituted in 200 μl of acetonitrile:water, vor-
texed for 20 s, and centrifuged at 13,300 rpm for 15 min. The undiluted sample was
used for glucose measurements while a 30-fold diluted sample was utilized for
lactate measurements. Samples were measured in analytical duplicates with each
sample set run in a randomized manner with pooled quality control samples
measured at the start of the run, after every 10th sample, and at the end of the run.
For both glucose and lactate measurements, 2 μl of each sample was analyzed in a
manner similar to the methods previously described59,60, modified for isotopomer
analysis. Targeted multiple reaction monitoring (MRM) methods were utilized to
detect lactate and glucose isotopologues in each respective run. Data were pro-
cessed and integrated using Waters TargetLynx software (version 4.1) with natural
abundance correction and further processing of ion counts performed in R.
Metabolic measurements for 1-13C-glucose experiments was measured with
Agilent LC-QTOF 6545. Metabolites were confirmed by running standards in
parallel. Isotopic labeling was measured using Agilent MassHunter Profinder v.
B.08.00 (Batch Isotopologue extraction) and the personal compound database and
library (PCDL).
Flux measurements in Bmal1−/− mouse skin fibroblasts. MSF cells collected at
each time point were washed with ice-cold PBS three times and then homogenized
in 1 ml 80% methanol (precooled at −80 °C). Samples were then flash frozen in
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liquid nitrogen and were stored at −80 °C until extraction. In the extraction
process, mild sonication was applied to the samples for 10 min (30 s on, 30 s off;
medium power) using a Bioruptor Standard (Diagenode) instrument. Then the
samples were vortexed for 20 mins at 4 °C and the lysates were centrifuged at
14,000 rpm for 20 min at 4 °C. Supernatants were carefully separated and trans-
ferred into new microcentrifuge tubes. Samples were dried by vacuum cen-
trifugation and were stored at −80 °C until GC-MS analysis for flux measurements.
Gel electrophoresis and immunoblotting. At each time point during a time
course, samples were removed from the incubator and 75 μl of RBCs (and medium)
from each sample tube lysed in 250 μl of 2× LDS buffer (Life Technologies) and
placed in a thermomixer heating block (Grant Instruments, model PHMT) for 10
min at 70 °C at 800 rpm. Immediately, samples were flash frozen in liquid nitrogen
and stored at −80 °C until analysis. Samples were allowed to reach room tem-
perature before analysis, which was performed as described previously11,15,28.
Briefly, NuPAGE Novex 4–12% Bis-Tris gradient gels (Life Technologies) were
loaded and run with a non-reducing MES SDS running buffer as per the manu-
facturer’s guidelines. Protein transfer to nitrocellulose membrane was performed
using the iBlot system (Life Technologies) with a standard P3, 7 min protocol. The
nitrocellulose membrane was blocked for 1 h at room temperature in blocking
buffer, composed of 0.5% w/w BSA, (Sigma A7906)/non-fat dried milk (Marvel) in
Tris buffered saline/0.05% Tween-20 (TBST). After blocking, membranes were
incubated with 1:10,000 anti-PRDX-SO2/3 antiserum (Abcam ab16830), diluted in
blocking buffer, overnight at 4 °C. The following day, blots were washed for 3 × 5
min in TBST and then incubated for 1 h at room temperature with a 1:10,000 HRP-
conjugated secondary antiserum (Sigma A6154). Blots were washed 4 × 10min in
TBST before performing chemiluminescence detection using Immobilon Forte
reagent (Millipore). Equal protein loading in each lane was checked with the aid of
gels stained with Coomassie SimplyBlue SafeStain (Life Technologies). Coomassie
stained gel images were obtained using an Odyssey system (Licor Biosciences).
Immunoblot membranes were scanned using an Amersham Imager 600 (GE
Healthcare). Quantification of images was performed using NIH Image J
software11,16.
NADH and NADPH assays. At each time point, samples were collected from the
incubator and centrifuged for 2 min at 375 × g at 4 °C. RBC pellets were washed
with ice-cold PBS twice and then centrifuged for 2 min at 375 × g at 4 °C. Super-
natant was discarded and the RBC pellet flash frozen in liquid nitrogen and stored
at −80 °C. Extraction of metabolites was performed with the buffers supplied with
commercial assay kits following the manufacturer’s instructions (Abcam ab65348
for NADH and ab65349 for NADPH measurements). Colorimetric measurements
were made at 450 nm absorbance and at 25 °C using a PerkinElmer Ensight
multimode plate reader. NADH and NADPH concentrations were determined
from a standard calibration curve according to the manufacturer’s instructions.
NADH/NADPH absorbance measurements were acquired using Kaleido pate
reader software.
Cell viability assays for metabolic inhibitor experiments. RBCs were isolated
from donors as mentioned above. The RBC pellet was made up to 9 ml with Krebs-
Henseleit Buffer. 420 µl of RBCs were aliquoted into the wells of a 96 deep well
plate for drug addition. 2.1 µl of diluted drug (1:200 dilution; 0.5% DMSO final)
was added to each well and mixed thoroughly. For 6AN, concentrations were
screened from 0 to 10 mM. For heptelidic acid, concentrations were screened over
the range of 0 to 1 mM. Fifty microliter of RBCs preparation with compounds
added (and control RBCs with only 0.5% DMSO added) were aliquoted into 96-
well plates. The plates were incubated at 37 °C in constant darkness. Sampling was
then performed every 24 h over a period of 96 h. At each time point, RBCs in a
plate were re-suspended by pipetting up and down. The 96-well plates were then
spun for 5 min at 375 × g and 25 µl of the supernatant transferred into a 384-well
plate for assaying. A standard curve was prepared by lysing untreated cells with
water (hypotonic lysis) and then performing serial dilutions in a 96-well plate. The
absorbance of the sample supernatants was measured at 480 nm (in a 384-well
plate) and using a Tecan M1000 plate reader. Red cell absorbance measurements
were acquired using Tecan M1000 plate reader software.
Red cell microscopy. During the circadian time course with metabolic inhibitors,
10 µl of sample was collected at specific time points and spread onto a microscope
slide (Thermo Scientific Superfrost Plus) and air dried. Microscopic images were
captured using a Leica DM IL LED inverted microscope with LAS software
version 4.8.
Quantification and statistical analysis
Mass spectrometry data processing, identification and meta-
bolite enrichment analysis. Vendor specific LC-MS raw data files
from the mass spectrometer were extracted using Progenesis QI
for metabolomics using parameters: feature detection= high
resolution, peak processing= centroid data with 70,000 (FWHM)
resolution. In positive ionization mode, M+H, M+ 2H, M+
Na, M+NH4, in negative ionization mode, M-H, M-2H, M+
Na-2H were considered. Agilent Mass Hunter software v B.07.00
was used to extract GC-MS data. Features having a coefficient of
variation (CV) lower than 30% among quality control samples
were selected for downstream analyses and features having CV
more than 30% were dropped from the dataset. We detected
1,698 features that had a coefficient of variation <30% in quality
control samples. This included 533 features from negative mode
LC-MS and 1074 from positive mode, with an additional 91 from
GC-MS. Metabolite Set Enrichment Analysis was performed
using Metaboanalyst software v 4.0, implemented in the R pro-
gramming language.
Rhythmic metabolites were identified using retention time and
MS/MS spectra of metabolite standards for LC-MS samples.
Retention time and MS spectra from GC-MS analyzed samples
were compared with metabolite standards and the National
Institute of Standards and Technology (NIST) mass spectral
library to confirm identification. The maximum number of
metabolites detected in the RBC metabolome until now is 21357.
The percentage of rhythmic metabolites in this study is 21% (46
rhythmic metabolites from total known RBC metabolome, i.e.,
213 metabolites).
Metabolic flux calculations. Metabolic fluxes were estimated by
using previously well-established models23,58,61,62. Briefly, the
Pentose Cycle (PC) can be estimated using NMR by measuring
differential enrichment of C3-lactate and C2-lactate after feeding





Where PC refers to fraction of glucose used to produce pentose
phosphate pathway-derived Glyceraldehyde-3-phosphate.
Differential enrichment of 13C1-lactate (m+ 1) and 13C2-
lactate (m+ 2) determined using GC-MS can be used to estimate
fluxes after feeding cells with 1,2-13C2-Glucose with the formula:
Mþ 1ð Þ Lactate
Mþ 2ð Þ Lactate ¼
3PC
1 PC ð2Þ
Metabolic fluxes for various metabolic pathways can be
calculated from PC and glucose uptake as follows:
PPP flux ¼ PC ´Glucose consumption ð3Þ
Glycolytic flux ¼ 1 PCð Þ ´Glucose consumption ð4Þ
Rhythmicity analysis. Analysis of circadian waveforms was
performed using two independent statistical methods22, the
Rhythmicity Analysis Incorporating Nonparametric method
(RAIN)18 and a harmonic regression method (ARSER)22,63,
which are implemented in the R programming language. P-value
outputs are shown for each plot, along with the best-fitting period
(e.g., for short or long period oscillations that deviate from 24 h).
Only P-values for RAIN analyses are shown in the text and fig-
ures, but the alternative rhythm detection algorithm ARSER
yielded results matching RAIN. Plots were produced in either R
or GraphPad Prism (version 7 and 8). Statistical parameters such
as details of replication and error bar meaning were reported in
the figure legends.
Bioluminescence assay analysis. Exported images were quanti-
fied in a time series using NIH Image J software. Circadian
rhythmicity in bioluminescence data was measured using a
modified version of the R script “CellulaRhythm”28,64.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data are available from the authors upon request. Source Data are provided with the
online version of the paper: for Fig. 3D it is provided in Supplementary Fig. 2 and
Supplementary Fig. 3, that for Fig. 3G in Supplementary Fig. 4 and Supplementary Fig. 5,
that for Fig. 5D in Figs. 5 and 6 in Supplementary Fig. 8, and that for Fig. 7C, D in
Supplementary Fig. 9. Metabolomics data for Fig. 1 can be accessed on the Metabolights
platform; Study submission code: MTBLS1285 and link https://www.ebi.ac.uk/
metabolights/MTBLS1285. Source Data for flux experiments for Figs. 3B, C, E, F, 4A, B,
6D, E, 7B, D–F are provided in an Excel spreadsheet. The remaining data are available
from the authors upon request. Source data are provided with this paper.
Code availability
RAIN and ARSER codes adapted from Thaben and Westermark18 and Yang et al.63,
respectively. Bioluminescence Circadian-R script “CellulaRhythm” was adapted from Rey
et al.28 and Hirota et al.64.
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